PATHOLOGY
TECHNOLOGY
AUSTRALIA

Annual Report **2021**

“The power of our technologies, diagnostic tests, and our industry are the drivers of innovative healthcare strategies and outcomes.

Our solutions are most often found in public and private pathology laboratories across Australia, and increasingly at the point-of-care, for HIV, diabetes and home glucose tests.”

Table of **Contents**

Chair's **Report**

I am pleased to provide my first report as Chair of Pathology Technology Australia (PTA) and I wish to thank all members from the outset for your commitment and support. Our objective remains to advocate for a market environment that embraces and adopts the innovative diagnostic technologies our members deliver.

As the global pandemic continued to destabilise economies and societies in 2021, the importance of pathology technology and the role we play in supporting the health ecosystem was increasingly recognised across many segments of society.

Since its inception as IVDA in 2010, our industry association has focussed on increasing our relevance to the Australian healthcare ecosystem. As the peak body for global and local suppliers of innovative diagnostic technology, we have endeavoured to give the membership a voice contributing to the national healthcare dialogue.

I believe that over time, 2021 will be viewed as a watershed year for our industry association – the year when PTA came of age. The year our relevance was increasingly recognised by ministers (state and federal), government departments, parliamentary committees, the media, commercial enterprises, and the wider community. More importantly, due to the efforts of our CEO, Dean Whiting, and support from the membership, 2021 witnessed the tangible influence PTA has had on the delivery of diagnostics within the health system.

On 24 March 2021, the Honourable Minister for Health and Aged Care, Greg Hunt, opened our Innovation Day in Canberra and used the platform to announce that point-of-care (POC) glycated haemoglobin (HbA1c) tests will be listed on Medicare, from 1 November 2021. This means that 190,000 tests for Australians with previously diagnosed diabetes are to be government funded when performed "in the doctor's surgery" to provide "immediate results."

Whilst the significance of this announcement for the one in twenty Australian adults living with diabetes is unmistakeable, its importance for PTA cannot be underestimated. Apart from his attendance at the PTA Innovation Day, Minister Hunt's opening address signified a breakthrough for PTA as it saw our purpose coming to life. The adoption of HbA1c point-of-care test (POCT) was the result of a 6-year effort by member companies, working together under the auspices of PTA, to highlight to policy-makers the ability of POCT to reduce the burden on patients and the health system. Evident in this announcement is that policy-makers now viewed PTA as a significant body from which additional information and perspectives can be attained, when they are considering the role of innovative technologies in shaping the future delivery of healthcare in Australia.

Likewise, the events of the last 2 years have highlighted the important role diagnostic suppliers play in the rapid adoption of innovative technologies. From the outset of the pandemic, the ability of pathology technology suppliers to develop, manufacture, supply and support innovative technologies at an industrial scale, drew attention to the importance of the PTA membership in the national pandemic effort. As a result, our

partnership with the TGA has strengthened whilst relationships with federal and state departments of health have grown significantly.

More recently, Dean Whiting has initiated or participated in many discussions pertaining to the national pandemic response – namely, the deployment of rapid COVID testing to reduce the burden of lockdowns and prevent overwhelming our PCR testing facilities. This has included discussions with numerous government agencies, bureaucratic committees and media outlets seeking input from our CEO. For a period, it became customary to see Dean on morning and evening news programmes, being interviewed alongside prominent professors in epidemiology, and in newspaper articles that either quoted, or were authored by, our CEO.

As a result, PTA is well positioned to continue to build our relevance and deliver on our purpose. Our membership and financial position remain strong, whilst our profile continues to build through numerous media and social media activities.

In March our membership came together to develop and agree on the 2022-2025 strategic imperatives. The consensus was to continue increasing our relevance and boldly position ourselves as a respected industry body whose input and perspectives are consistently sought by policymakers. Our success will be determined by our ability to collaborate with other industry stakeholders and leverage the inherent value encompassed by the broad PTA membership – that is, years of expertise and depth of knowhow in developing and supplying innovative technology that will shape the delivery of diagnostics in Australia. Consequently, a PTA Government Affairs advisory panel, comprised of individuals with relevant experience from PTA member companies, has been formed to guide our collaborative efforts within the health ecosystem, bureaucracy and government.

I would like to thank Dean Whiting for his tenacity and commitment in delivering on the PTA strategy and putting our association in such a well-established position – a position best characterised as 'aspirational' a few years ago.

Similarly, thank you to our committees, who drive the outcomes of our strategic plan. Without their commitment and dedication, our current position could not have been possible. I would also like to acknowledge the contributions of Jenny Zhao (Tecan Australia) who was CPA to the Finance, Audit & Risk Management Committee. Jenny has now moved to a role in San Francisco with Tecan and therefore passed this responsibility onto Olivia Ching from Werfen Australia. Welcome Olivia! A special thank you to our Secretariat, Chami Gunasinghe, who is the glue that keeps everything together in the background. Thank you all; a great Team!

I must express my appreciation to the Board of Directors for executing their duties with distinction and providing sound counsel to both Dean and myself. I want to recognise the contribution of Mark Volling (Abbott Laboratories), Sally Hickman (Werfen Australia), Antoinette Violo (Perkin Elmer), Karen MacLeod (MP Biomedicals), Jenny Carson (Siemens Healthineers) and Vito Trifilo (Tecan Australia) for the commitment and hard work. Unfortunately, 2021 saw two board directors resign their position due to career changes; Nic Latouche (formerly with Bio-Rad Laboratories and now at Abbott Laboratories) and Tony Feneziani (formerly with Merck Group and now at Cepheid). Although Nic was a director for a short period of time, he continues to serve as Chair of the Market Development Committee (for just over two years) and was instrumental in devising and organising the PTA Innovation Day in Canberra. Tony was a board director for three years and his sound judgement and unique perspectives will be missed on the board. Nonetheless, the board was pleased to recently welcome Colin Denver (SpeeDx) and Murray Dunning (Beckman Coulter) who have demonstrated an immediate impact by contributing to the high quality and diverse thinking required to maintain the level of board effectiveness expected of our membership.

Finally, I wish to express my gratitude to all our members for your support and commitment to our objectives. It demonstrates the genuine character of our industry association, and its purpose, when, members with differing commercial interests are aligned in advocating for an environment where the latest innovations in diagnostic technologies can sustainably be delivered to improve the health of all Australians.

David Basseal
Chairman, Pathology Technology Australia

CEO's **Report**

Who could have predicted the turn of events in 2021? I am sure many of us were pleased to leave 2020 behind, thinking the new year would be better, but COVID-19 has intervened again.

While lockdowns, reduced (non-COVID) testing numbers and escalating freight costs have been a clear downside, the upside has been significant for our profile and notoriety. For example, we held our first ever Pathology Technology Innovation Day inside Parliament House Canberra. Greg Hunt, the Minister for Health opened our Day, and in doing so, announced the approval of our long fought for MBS item number, funding HbA1c tests at the point-of-care (POC). We have been invited to hold regular one on one meetings at the highest levels in the Commonwealth Department of Health. We now have a media profile and are approached by mainstream TV, radio, print and online agencies for contributions.

But let's dwell for a moment on the importance of the MBS item number approved for HbA1c testing at the POC. This is reward for a huge investment in time and funds over 6 long years. It is the first IVD we have had funded for general use at the point of care. Given the barriers we encountered during those years, this achievement is a testament to the persistence of a few hardy souls. This experience has taught us a lot about MBS funding and given us an opportunity to discuss alternative funding mechanisms with the Commonwealth.

We achieved another of the major milestones during the year, the first comprehensive market data survey of tests supplied into the Australian market. The majority of members participated and contributed. The contributing members have access to their own market data in comparison to the total market. The view I have is of the total market, and what a view it is. There are about 40% more tests consumed in the market than traditional wisdom predicted. The COVID slump is clearly visible in the 3-year trend. This data would be highly valued by health strategists and funders, and it is up to members to decide if and how we leverage that value.

Membership numbers were up again in 2021, as was revenue. But most importantly, we are making tangible headway in being recognised for the role we play in enabling the high quality, accessible and affordable health ecosystem we have in Australia.

The three-year strategic plan we set out in 2019 has been achieved a full year ahead of time. Our new strategic plan, developed at our well attended strategy day in

March, sets out some aggressive new objectives, built on the foundations we have already set. As you can see below, we have pivoted from the inward focus that we used to rebuild, to an outward focus where we recruit and collaborate with other stakeholders to build our profile

- Increase and expand collaborations with relevant groups to accelerate change (for better, more effective use of pathology technology).
- Identify new ways of working with key influencers.
- Challenge the status quo for existing funding models (suggest alternatives or improvements).
- Increase the perceived value of pathology technology with both consumers and politicians
- Expand local capability, specifically in manufacturing and supply chain

Our standing committees already have projects up and running that will help deliver our strategic elements. We have budgeted to support these projects and to resource them for maximum effect. I am particularly excited about building our collaborations with consumer groups and key influencers. Likewise, I am very keen to demonstrate our value to the health ecosystem with more market data and a comprehensive technology expo, which we are planning for H2 2022.

We have extended our, already very good relationships with the TGA, to a level where we meet quarterly specifically on IVD topics and hold dedicated workshops with key staff as needed. The head of TGA, John Skerritt, and the Department Assistant Secretary, Tracey Duffy, attended our December TARSC meeting, where we exchanged compliments and discussed the future challenges we can address together.

COVID-19 has presented us with our greatest ever change agent.

It has given us opportunities to access levels of government and bureaucracy not previously enjoyed. We have had particular focus on Rapid COVID Testing to leverage our profile with governments, private enterprise and the media. We now have profiles with key politicians, Commonwealth and (some) state Health Departments, major business groups, unions, the RACGP and the Pharmacy Guild.

The focus on rapid COVID tests is a means to an end; it gets us closer to the table. There is a much bigger vision we can drive here; improving patient outcomes by improving access to the innovative technology our members deliver: Technology vital to high quality, affordable and accessible healthcare for all Australians.

I envisage that we will now be leveraging our rapid COVID testing experience and our improved access, to shine the spotlight on the value of our technology in:

- Molecular and companion diagnostics
- Point of care testing, and possibly home testing
- Digital pathology and software as a medical device
- Challenging the status quo in funding pathology tests

The barriers to success are still there, and we need to be persistent, diligent, fact based, but above all, we need to be united. I am encouraged every day by the calls of support and great ideas coming from members. I am motivated by the prospect that we can take our place as an equal in the healthcare ecosystem.

We can't do this without you. Likewise, our standing committees and our expert panels play a vital role. I am very grateful for the fine work our committees are doing, from the Finance and Risk, to Technical and Regulatory Affairs, our Market Development and Marketing Communications committees. It is great to have your support and I appreciate the work you do very much.

I also want to acknowledge the fine support provided by Chami Gunasinghe to me and to the membership of our organisation.

I look forward to your continued support, feedback and ideas as we – together - deliver the innovative products and services that drive high quality, accessible and affordable healthcare in Australia.

Dean Whiting
CEO, Pathology
Technology Australia

Pathology Technology Australia **3 Year Plan**

Build 2021

- Complete stakeholder mapping and create the key messages and value proposition for each stakeholder group
- Complete list of key influencers and provide tailored key messages for each
- Use compelling health economic and other data to inform policy and funding for pathology technology
- Develop a position paper on alternative on pathology funding in Australia
- Initiate policy discussion on new technology, solutions and software

Realise 2022

- Establish and execute stakeholder influence program
- Train, cultivate and deploy key influencers
- Be an adviser to government in direct meeting, and via advisory committees & working groups
- Initiate policy discussion on new technology, solutions and software; actively promote local capability, specifically manufacturing and supply chain

Achieve 2023

- We are invited to provide information, data and trends to inform better policy and funding decisions
- Valued for the new technologies and solutions we bring the health economy
- We actively showcase our technology and continue to support PAA
- Key political and public service stakeholders articulate the value pathology technology delivers to healthcare and the health economy

Treasurer's **Report**

I would like to present the Pathology Technology Australia accounts for the financial year ending June 30, 2021. The accounts, audited by Nexia Australia, are included in this annual report and are available to those who wish to obtain a copy.

The main work of the Finance, Audit & Risk Management (FARM) Committee has been in financial stewardship and ensuring that our members are experiencing value for money.

Through clear strategic planning, a strong focus on new members and associates, diligent risk management and cost control; we will continue to ensure the financial stability and security of the organisation. We plan on investing in strategic projects with a greater presence engaging, and lobbying government stakeholders. Stronger social media presence will continue to be utilised to showcase how our technology delivers important healthcare outcomes.

I can report that our income for the year of $618,833 was well above budget ($525,000). This achievement was due to a combination of membership, events and interest. This total income increased by 133K on last year's number.

Our expenditure for the year was $560,737, slightly under our budget of $563,432. Expenses were higher than the previous year by 143K. An increase in Business Development, Strategic Projects, and computer/video conferencing costs were the main reasons behind this. Most of the computer/video conferencing expenses were offset by savings in travel expenses.

Strategic Project expenses accounted for $155,531 vs 2020 (of $58,970), and included Pathology Awareness Australia membership, our new market data project establishment costs, an industry-based Innovation Day conference staged at Parliament House in March, and strategic social media projects.

Full details of the income and expenditure can be found in the accounts published in this report.

I would like to thank the FARM committee; Dean Whiting (CEO), David Basseal, Sally Hickman, Jenny Zhao (CPA) and Chami Gunasinghe for all the time and effort put into helping us to strive for financial stability and diligent risk management.

In summary, as a not-for-profit organisation, I am pleased to report another successful year. The financial position of Pathology Technology Australia is stronger than ever, due to the increase in income driven by a larger membership base and and continued diligent expense management.

Thank you and best regards,
Vito Trifilo

Board of **Financial Statements & Financial Report**

- MYOB is fully reconciled with bank statements.
- Turnover Declaration from Thermofisher has now been received and invoiced (in September).
- Current receivables (31st August) sit at $151,565 with about $45,000 further membership receivables to be added in Sept.
- Expenses running under budget at the moment with several notables:
    - Website invoice part-paid in June
    - Still no travel costs, despite budgeting for this
    - Journaling in and out of audit expenses
- Draft Audit report back from Nexia.
- After the Audit is complete, we can complete the rollover in MYOB.
- Once the rollover is complete future MYOB reports will include comparison to past year as well as the budget.

Assets & Liabilities

- As at August 31st our MYOB balance sheet shows total assets is at $1,061,418 of which $903,703 is cash at bank (tied back to bank statements).
- This includes $240,091 and $80,069 in our Westpac investment accounts.
- We have $151,565 outstanding debtors (new membership invoices), down from $293,245 as at July 31st.
- Current total liabilities run at $116,232 of which $29,386 is provision for employee benefits, $26,304 is payroll tax and $58,967 is GST on new memberships.
- Net equity sits at $947,847.

Cashflow Projections as of 31st August show approx $110,000 surplus to 30 June. The proposal to renew our successful PR campaign with London Agency was approved by most Directors. This constitutes an unbudgeted expense of $40K, well within our projected surplus.

Also, for your information, the financial graphs proposed for the Annual Report.

REVENUE 2018 TO 2021



BUDGET TRENDS



EXPENSE BREAKDOWN



Assets & Liabilities

- We have budgeted to utilise funds not spent last FY on travel and meetings on new value add activities and projects.
- Despite having expenses greater than revenue in 2022 we maintain a cashflow positive balance.
- Employment expenses increase as a percentage of total expenses in the second half of 2022 when we hire an assistant manager.

Finance, Audit & Risk **Management Report**

The main focus of the Finance, Audit & Risk Management (FARM) Committee has been the financial stewardship to ensure our members experience best value for money.

As a not-for-profit industry organisation, we have limited financial resources. Our primary responsibility is to our members.

As recipients of member funding, we also have a responsibility to use our resources wisely. These factors mean that the board's attitude to risk is generally cautious. It is also the responsibility of the Board, delegated to the FARM Committee with the assistance of the CEO, to carry out risk management analyses of the organisation, and to take appropriate measures.

Therefore, the FARM Committee ensures that:

- our financial viability is maintained through prudent budgeting, expense management and regular review of financial reports
- effective risk management procedures are in place, applicable to all relevant areas
- risk management procedures are reviewed regularly
- recommendations arising out of the risk management process are evaluated and, if necessary, implemented
- employees are aware of all applicable risks and familiar with the organisation's risk management procedures.

Of further focus in 2020-21, has been the Risk Management Register, which has been strengthened with the inclusion of a Mitigation & Action Plan dashboard.

Members of the current committee are Dean Whiting (CEO) David Basseal, Sally Hickman, Jenny Zhao (CPA), Chami Gunasinghe (Executive Support) and me as chair. We meet every six weeks to review the current financial and risk position of our organisation with the goal of financial stability and diligent risk management. Jenny Zhao has provided expert advice and guidance over the past year but has now accepted a new position in the USA and has re-located with her family. We thank her for the excellent support she provided. We now welcome Oliver Ching (CPA) to the committee to continue in the tradition Jenny has left.

Given our strong 2020-2021 year, due to increased income and decreased expenditure, we have carried over a larger surplus than budgeted. Our goals for 2021-2022 are to continue to grow our membership base and to judiciously deploy the surplus on strategic activities that drive member value. While we will continue to be vigilant on costs, we are projecting a (cashflow neutral) loss approximately equal to the surplus we carried over. The FARM Committee will continue vigilance on risk, risk assessment and financial security. A stronger focus for the new year will be placed upon establishing, implementing and execution of succession plans.

Thank you and best regards,
Vito Trifilo

FARM Team in 2020-2021:

Vito Trifilo (Chair)
David Basseal
Sally Hickman
Dean Whiting
Jenny Zhao
Olivia Ching
Chami Gunasinghe

Technical & Regulatory **Standing Committee**

The Technical and Regulatory Standing Committee focuses on advancing Regulatory awareness and positively impacting Regulatory requirements.

Delegates of TARSC have attended the TGA RegTech Forum and DAWE Biological Consultative Group meetings and in these have had successes in clarifying requirements, reviewing guidance documents, along with monitoring and raising awareness of impending Regulation change impacts.

These outcomes are often mentioned in the CEO Newsletters as key topics of interest to our members. Some examples include the Self-testing IVD guidance and IVD Companion Diagnostics Regulation and Guidance in the second half of 2020.

We have seen TGA significantly increased their Customer and Industry involvement:

- most recently by joining our committee calls (to discuss specific topics)
- their presence on industry-wide discussions on GS1 Recall Health Advisory Group Meetings (for example)
- with our TARSC team leaders in joint discussions with the BICON team at the Department of Agriculture, Water and Resources.

In addition, TGA are using LinkedIn, Emails and Website announcements to advertise their UDI programme planning and Digital Transformation workshops to ensure a wide range of users can attend. We've also invited TGA to speak directly to TARSC on these topics. We were very pleased to have Adj Prof John Skerritt (head of TGA) and Ass Sec Tracey Duffy join our TARSC Team call in December.

An important project that we have been work closely with the TGA on is the introduction if the European IVDR changes. We have been holding workshops with the TGA which members have found extremely helpful. Australia is relatively well placed to embrace the IVDR changes, having taken steps in this direction several years ago. However, there is still a great deal of work to do on both company and regulator side to meet the deadlines looming in May 2022.

For some time now, we have been planning with TGA to provide training courses. These will take the form of 2 half-day courses, one aimed at foundations understandings of the regulatory requirements in Australia and the other aimed at a higher level of advanced topics such as device change requests. This training plan has been put onto the back burner while we all work on COVID and IVDR.

TARSC Team in 2020-2021:

Melissa Robins (Chair)
Karen MacLeod
Libby McDermott
David McLean
Aileen O'Connor
Erica Loh
Robyn Smyth
Peter Traynor
Lazarela Vucinic
Merrilyn Colussi
Neralie Coulston
Dean Whiting
Terrance Thiel
Alex Leung
Michael Gunter
Hoon Koh
Elizabeth Freitas
Maureen Flores

Marketing Development **Committee**

The Market Development Committee (MDC) is focussed on raising the overall awareness of the role technology plays in a healthy pathology sector. The MDC aims to deliver value by driving projects that increase market growth and access for Pathology Technology Australia members.

Over the course of 2020-21 the MDC met monthly and, in the months preceding the Canberra innovation event, the MDC met fortnightly.

MDC Objectives:

- Deliver value by collecting relevant and current sales data from members to provide regular consolidated market trend reports to members
- Support members by creating opportunities for joint supplier funding submissions to MSAC
- Leverage our member's combined knowledge and experience to provide industry specific comments and position statements to influence outcomes in policy, regulatory and funding decisions
- Help raise awareness to the value of technology in Pathology by looking for opportunities for PTA members to interact with key stakeholders and decision makers.

Current projects underway led by the MDC

1. Health Economics Project: This project is aimed at developing a process for collecting meaningful data from members to generate an overall picture of the size, growth and trends in the pathology market. This project is aligned with the PTA goal to provide value to members. In last year's report, this project had kicked off with discussions around the list of assays that would be included in Phase 1 and the platform for the impartial and confidential collection and reporting of data. In March 2021, the first survey was sent out to members by our data integration partners, 10 Thousand Feet (Sydney). The results were sent out to members in May 2021 with initial feedback being very positive. The survey, sent to members in Q3, collected feedback on the process and the data they received, with a view to continuous improvement. In addition, the MDC has started to review additional tests that could be included, using the same criteria as that used for Phase 1, into Phase 2 of this project. The second market data collection survey is in process and members will have results at about the time this annual report is published.

2. Leverage PTA members' expertise and experience to draft joint MSAC submissions. This project aims to tap into the experience member companies have had in submitting MSAC submissions to maximise successful future joint submissions. This project is also aimed at providing value to PTA members with the understanding that submissions from industry groups are more likely to be successful than those from individual companies. In 2020, the MDC completed a review of the first successful

MSAC submission in many years, HbA1c at point-of-care. In 2021, the MDC has created a sub-committee of members with experience in MSAC submissions to achieve the following:

a. Develop a process for collecting a wish list from PTA members for consideration for a joint submission

b. Develop a set of criteria to prioritize the list based on member requests, while also (not exclusively) considering the needs of external stakeholders such as the Royal College of GPs. It is intended that no more than 1-2 submissions will be made each year, with approval from the PTA board.

c. Work with relevant members, and external groups where appropriate, to draft submissions that benefit PTA members.

3. Raise awareness of the value of technology to pathology project. In 2021, the MDC worked with the Market Communications Committee (MCC), PTA board members, and London Agency to plan and organise a technology event day at Parliament House on the 24th March 2021. The objective of this event was to drive greater awareness of the role that pathology technology plays in healthcare with a key stakeholder group, namely federal parliamentarians and other government officials. The event was a great success by all metrics, including attendance by parliamentarians, new connections made, media interest, meetings requested with PTA following the event, interactions on social media and via the PTA website. The most important outcome of the event was the live announcement by The Hon Greg Hunt MP for HbA1c re-imbursement for point-of-care testing (POCT) starting from November 2021.

Future projects: In May 2021, the MDC met to review the key objectives that came out of the PTA strategy planning day held in March. In discussions with the MCC, the MDC adopted the following projects for the rest of 2021 and 2022.

(A) Work on the final list of tests for Phase 2 survey of the health economics project. Capture feedback for improvement from members.

(B) Work with broader members of PTA to develop a process for joint, industry wide, impactful MSAC submissions.

(C) Continue to raise awareness to the value of Pathology technology to a variety of stakeholders by holding a PTA Technology Showcase event in the second half of 2022.

(D) Identify new opportunities to interact with PTA stakeholders by developing relationships with relevant external groups.

(E) Work with relevant members to advocate, position and expand local capability, specifically in manufacturing and supply chain

Market Development Committee in 2020-2021:

Nicolas Latouche (Chair)	Jackson Jones
Dean Whiting	Jennifer Devereaux
Karen MacLeod	Ben Smith
John Emmerson	Emily Mahon
Mark Volling	Chami Gunasinghe

Marketing & Communications **Committee**

The Marketing & Communications Committee (MCC) is responsible for developing and implementing an integrated communications strategy that promotes the value of PTA to our members, the government, the community and other key stakeholders. The MCC provides strategic advice on the delivery of promotional campaigns, materials and events that are designed to increase awareness of the value that we bring.

FY2020 and 2021 has allowed us the opportunity to keep pathology technology firmly in the spotlight and the MCC has continued to seize the opportunity to increase the profile of our industry to both the government and to the wider community.

Much of the MCC activity in this financial year was centred around the highly successful Canberra Innovation Day. The MCC played a strong support role to the Market Development Committee (MDC) for this event, providing branding and key messaging for the day.

This fantastic event showcased the member companies behind the technologies supporting the diagnostics discipline. The objective of the MCC was to ensure that the parliamentarians that attended on the day walked away with a clear understanding of our key message that "Our technology makes pathology possible". Our social media reach was beyond expectations on the day, where at one point PTA were the highest trending profile on LinkedIn.

There were other key activities and achievements of the MCC in FY20-21 including:

- The development and roll of a detailed member survey. The member survey has been key to providing guidance to PTA on how to increase and maintain member value. The team at London Agency did a great job getting a high number of member companies participating. This survey provides valuable insights as to the perceived value of PTA and determining if we are heading in the right direction with our strategy.
- The MCC played an active role in turning outcomes from the Strategy Day into forward looking actionable projects.
- We launched "The Directors Cut", a social media campaign on Linkedin, involving a short video of each of the board members, highlighting their role in the industry and the importance of their role within PTA. This campaign is designed to raise the profile of each of the board members and of PTA by extending our social media reach.

- Social media posts have been a regular contributor to raising the profile and awareness of PTA to a broader audience.

Looking forward to FY21-22 we will be focussing on developing a communications strategy that supports PTA's key strategic focus areas. In the coming year our fundamental objective will be increasing the perceived value of pathology technology for all of our key stakeholders by:

- Developing a communications and media campaign that leverages the announcement by Minister Greg Hunt during the Canberra Innovation Day that HbA1c has been approved for a Medicare rebate in a point of care setting.
- Streamlining and updating our website to ensure we have clear messaging and easy access to resources for our members.
- Executive Breakfast meetings for member companies
- Social media campaigns to continue to raise awareness of our technology
- Continued support of the MDC particularly in the development of a "Technology Showcase" event.

> "I have the pleasure of working with all my fellow committee members and I wish to thank the participating member companies and staff of London Agency and for their involvement and participation in PTA events and activities."
>
> Jenny Carson

Marketing & Communications Committee:

Jenny Carson (Chair)

Antoniette Violo

Cate McGavin

Vicki Neal

Chami Gunasinghe

Dean Whiting

John Emmerson, Mike Dolan and Hugo Twopeny

Michael Wawrzyniak

Tony Bhalla

Code Administration **Committee Report August 2021**

There have been no Code of Practice violations reported during period July 1 2020 to June 30 2021.

Our Code of Practice is an important way we communicate our members' commitment to fair, ethical and compliant business practices. All member companies agree to abide by our Code when they join and when they renew their membership annually.

Our Code of Practice was a main pillar of this organisation when we first launched, 12 years ago. Since then, many of our member companies have instituted extensive codes of their own – with mandatory training, audit and certification processes. Many of these now meet or exceed the requirements set out in our Code.

Our Code of Conduct Commissioner is Mr David Harrison. David brings a wealth of experience into the role having recently completed his Australian Directors qualification and with his decades of focus on quality and compliance. David currently runs his own consultancy offering quality, regulatory and compliance process services to device manufacturers.

Our Code of Conduct Commissioner is responsible for:

- Accepting and investigating any complaints of Code violations
- Being available to assess member company codes to determine if they meet the threshold set in our Code
- Reporting on Code activities to the Board and membership.

In summary, our aims are –

- have the Code give clear guidance as to the business conduct expected for our sector;
- continue to maintain high standards in our Code of Practice;
- minimise duplication of effort for companies with comparable codes;
- strengthen our application of the Code of Practice by appointing an independent Commissioner.

As individual members and as part of our organisational activities we remain ever vigilant in our observation of our code and commitment to ethical and compliant business practices.

Canberra **Innovation Day**

24th March 2021 will go down in our organisation's history as the first day we were truly acknowledged for the vital role we play in the high quality, affordable and accessible healthcare system we enjoy in Australia. We held a Pathology Technology Innovation Day in Australia's Parliament, Canberra.

We were honoured to have the Minister for Health; Hon. Greg Hunt opening our event and to hear his expansive acknowledgement of the role our members play in healthcare. He made the surprise announcement of the reimbursement of HbA1c testing at the point of care. The first reimbursement application launched jointly by PTA and our members. Having the Minister attend was especially gratifying, given that he had only recently returned to work from sick leave, and he had cancelled all other external meetings for the day.

Because of COVID limitations we were required to significantly limit the number of members who could attend. Those that could were effusive in their praise for the event. So much so that we are already planning a much larger event for the future.

By all measures we hit or exceeded the metrics we set for this event:

- Hon Greg Hunt opened the meeting
- Attended by 12 federal parliamentarians
- Resulting in 5 immediate follow up, one on one meetings, and further 16 expressions of interest in meetings. Some of these meetings have now gone on to develop long term relationships with key parliamentarians.
- The event generated 100 new followers on LinkedIn during and in the days after the event, and generated over 3,100 impressions and messages
- At one stage we were in the top 1% of views on LinkedIn for the day.
- Our website saw a significant spike in visits.

The event not only provided a platform to display innovation, but it also provided an opportunity for parliamentarians and invited senior staff from the Departments of Health and Industry, Science, Energy and Resources to enjoy 2 seminar sessions. The seminars featured presentation from members and key experts such as Adj Prof John Skerritt and Prof Mary-Louise McLaws.

This event was just over 12 months in the making and huge credit goes to the Market Development Committee, led by Nic Latouche with great assistance from the Marketing & Communications Committee led by Jenny Carson. To all the committee members, substantial thanks for a great job.


PATHOLOGY
TECHNOLOGY
AUSTRALIA


PATHOLOGY
TECHNOLOGY
AUSTRALIA
TECHNOLOGY
AUSTRALIA
Abbott
DiaSorin
HOLOGIC


#wearePTA


PATHOLOGY
TECHNOLOGY
AUSTRALIA

Know Pathology Know Healthcare Report **The year that pathology mattered to everyone**

A quirk of COVID-19 is that the Australian public has never been more interested in the role of pathology in their healthcare delivery. We now have a very tangible reminder of how Australia's pathology system is integral in disease detection, management, and treatment, to keeps ourselves and our families safe.

For the better part of a year and especially for Australians living in Eastern seaboard States, the daily briefing from Premiers on the number of tests performed and with it the cases of COVID-19 detected, was the most important information in our day.

Behind the meteoric volumes of daily PCR tests are the stories of Australia's highly skilled pathology workforce working around the clock to produce these results.

For Pathology Awareness Australia and the Know Pathology Know Healthcare **(www.knowpathology.com.au)**, the pandemic has provided an opportunity to highlight the value of pathology technologies, those who use them, and the crucial role they play during this pandemic and beyond.

To add depth to the media stories on COVID-19 testing, Pathology Awareness Australia expert spokespeople made comment on how their work was central to the public health response and that COVID-19 was an example of the ways in which pathology is central throughout healthcare.

Amid the surge in COVID-19 testing, there was a marked decline in routine healthcare testing – an indicator of Australia's participation in wider healthcare. Pathology served as "the canary in the coalmine" to show that if Australians neglected their routine tests then the impact of COVID-19 could be dwarfed by the rises in preventable cancers and chronic diseases.

Building on the formation of the Continuity of Care Collaboration (CCC), a spin-off collective forged by Pathology Awareness Australia of more than 40 healthcare organisations to encourage Australians to continue engaging with routine health tests throughout the pandemic and beyond, Pathology Awareness Australia launched the "Don't Wait Mate" campaign. The social media and earned media campaign were embraced by businesses, politicians and celebrities to get the word out. It also saw Pathology Awareness Australia, Medicines Australia and London Agency win the Prime Awards best public health campaign.



This campaign has strengthened the ongoing ties between the pathology sector and related healthcare groups who are able to recognise and reflect our value to their audiences.

Pathology Awareness Australia was further involved in promoting recognition of areas of testing that continued to lag, such as cervical cancer. A multi-platform campaign to remind Australian women of the importance of screening has seen testing rates improve.

Amid the disruption of the last 12 months, a positive legacy is improved recognition of the opportunities from pathology and pathology technology to deliver better health outcomes for Australians.

Pathology Technology Australia is a member of Pathology Awareness Australia and a major supporter of the Know Pathology Know Healthcare program.

Director's **Report**

The directors present their report, together with the financial statements, on the company for the year ended 30 June 2021.

DIRECTORS

The following persons were directors of the company during the whole of the financial year and up to the date of this report, unless otherwise stated:

Mr David Basseal (Chair)	Appointed 26 February 2019 to present
Mr Vito Trifilo (Treasurer)	Appointed 17 September 2015 to present
Mr Mark Volling (Vice Chair)	Appointed 7 October 2020 to present
Ms Sally Hickman	Appointed 21 February 2018 to present
Ms Antionette Violo	Appointed 28 February 2018 to present
Ms Karen MacLeod	Appointed 28 February 2018 to present
Mr Tony Feneziani	Appointed 28 February 2018 to March 2021
Ms Jenny Carson	Appointed 7 October 2020 to present
Mr Nicolas Latouche	Appointed 7 October 2020 to March 2021
Mr Sebastian D'Angelo	Appointed 20 February 2014 to 7 October 2020
Mr John Crothers	Appointed 14 October 2011 to 7 October 2020
Mr Rayden Rivett	Appointed 17 September 2015 to 7 October 2020

COMPANY SECRETARY

Dean Whiting has held the role of Company Secretary since 18 March 2019.

OBJECTIVES

Pathology Technology Australia Ltd exists principally to facilitate the growth and development of the in-vitro diagnostics industry in Australia by increasing awareness of and advocating for, technology and tests that improve outcomes for patients and the healthcare economy.

Short term objectives

The Company's short term objectives are to:

- To retain and grow the diversity of members
- To maintain and grow a Reserve Fund of $240,000
- To present TGA regulatory support to members as required in 2020-21
- To ensure regular ongoing meetings with Members to determine the industry's key issues
- To work with Pathology Awareness Australia and other stakeholders to maintain the 'Know Pathology Know Healthcare' program.

Long term objectives

The Company's long term objectives are to:

- To cultivate the Association to a financially sustainable future, providing value added services to members
- Diversify revenue sources to include events management and market data reports
- To provide up-to-date industry and regulatory information
- To increase public and government knowledge and understanding of the value of the IVD industry
- To maintain recognition as the peak body representing the IVD industry
- To provide leadership in the commercial technical and regulatory environment in which members operate
- To operate a Code of Practice that is representative of the PTA and wider community with an equitable and transparent complaints process
- To demonstrate strong corporate governance of the sector
- To influence direct regulatory policy to the benefit of members.

STRATEGY FOR ACHIEVING THE OBJECTIVES

To achieve these objectives, the Company has adopted the following strategies:

- Grow current membership base by creating clearly identifiable benefits of PTA membership
- Set and manage budgets that include a contingency fund
- Actively encourage and support participation by all members
- Provide easily accessible relevant and current industry information to members
- Provision of quality training and networking opportunities for members
- Engage with RCPA, PPA, AP and other key stakeholders to build active co-operation and consultation on reimbursement issues
- Engage with all levels of government to ensure PTA is recognised as a key stakeholder in the pathology industry
- Develop relevant publications on topics that can demonstrate PTA's benefits to the community such as POCT, the role of diagnostics in prevention and treatment of chronic disease and the PTA code of conduct
- As the peak body for the IVD Industry, work with regulatory agencies and participate in government committees, taskforces and working groups, forums, committees and one-on-one meetings
- Monitor legislation and policies for their effect on IVDs
- Ensure that timely and transparent ballots are held for the Board and all Committees
- Create a clear and transparent Code of Conduct process
- Ensure fair and equitable representation of all members
- Create opportunities for members to proactively engage in Association activities
- Develop an understanding of IVD benefits within the Consumer Health Community
- Develop and promote a range of policies that support the IVD Sector including POCT, Chronic Disease, Pharmacogenomics and reimbursement
- Develop links with and enhance knowledge of the benefits of IVDs within the Health and Insurance sectors.

PRINCIPAL ACTIVITIES

The principal activity of Pathology Technology Australia Limited during the financial year involved facilitating the growth and development of the in-vitro diagnostics industry in Australia by increasing awareness of and advocating for, technology and tests that improve outcomes for patients and the healthcare economy.

No significant changes in the nature of the company's activity occurred during the financial year.

BUSINESS REVIEW

Operating results

The Company continued to engage in its principal activity, the results of which are disclosed in the attached financial statements. The net surplus of the Company for the financial year ended 30 June 2021 amounted to $113,563 (2020: $101,036).

Dividends

The Constitution of the Company does not permit the payment of dividends.

SIGNIFICANT CHANGES IN STATE OF AFFAIRS

No significant changes in the Company's state of affairs occurred during the financial year.

INFORMATION ON DIRECTORS

The names of each person who is a director at the date of this report are:

David Basseal (Chair) — **Chief Commercial Officer, Minomic International Ltd**

David Basseal has over 25 years industry experience in Life Sciences, 16 years of which in In-Vitro Diagnostics. David commenced his career as a research scientist in the field of proteomics before joining commercial enterprises in sales and marketing. Progressing through roles of increasing responsibility within multinational organisations that include Bio-Rad Laboratories, Becton Dickinson, and Roche, David is currently the Chief Commercial Officer with an Australian biotechnology company, Minomic International Ltd. David has a Bachelor of Medical Science (Hon), Master of Commerce, Master of Business Administration, and is a member of the Australian Institute of Company Directors.

Vito Trifilo (Treasurer) — **General Manager, Tecan Australia**

Vito has over 25 years' experience in the Life Science and In Vitro diagnostic businesses in the Australian and New Zealand. Holding business development and sales management roles with multinational companies such as Millipore and Merck for over 15 years and was an early company representative with AMRAD Pharmacia Biotech during the start-up phase. Vito's current role is General Manager at Tecan Australia (a position held for over 8 years); with ANZ sales, marketing, legal and regulatory responsibilities. Tecan is a leading global provider of laboratory instruments, reagents and solutions (strongly automation focused) in biopharmaceuticals, research, forensics and clinical diagnostics. Vito holds a Bachelor of Science degree in Biochemistry and Genetics from the University of Melbourne.

Mark Volling (Vice Chair) — **Managing Director for Abbott Rapid Diagnostics in Australia & New Zealand**

Mark has over 35 years' experience within the Australian IVD industry including senior roles within global IVD companies, local manufacturing/export and distributor only organisations. Previous to Abbott, Mark was the Regional Managing Director for Alere/Inverness Medical in Australia and New Zealand and was the local lead in Inverness Medical's acquisition of Panbio Ltd which closed in January 2008 and subsequent health management acquisitions and divestitures. Mark possesses an Associate Diploma in Clinical Laboratory Techniques (QIT), Bachelor Business in Finance/Accounting (USQ), Graduate Certificate in Management (USQ) and a Masters of Technology Management (UQ).

Sally Hickman

General Manager, Werfen Australia & NZ

Sally has over 12 years' experience in the Australian IVD industry having undertaken key roles in the areas of strategic marketing and customer account management. In 2012, Sally joined Werfen Australia and assumed key management responsibilities at a time when company took direct operations of key business units in Oceania. Sally has a passion for diagnostics having trained and worked in public pathology laboratories for more than 5 years in the UK. Sally holds a Bachelor of Science degree in Biomedical Sciences from The University of Bradford, UK and a Master of Science in Biomedical Sciences degree (specialising in Haematology) from The University of Ulster, UK.

Karen MacLeod

Director and Country Manager, MP Biomedicals

Karen's 30-year career in the in-vitro diagnostics and pharmaceuticals industries began as a medical scientist in public pathology and includes varied sales and management roles with Australian based global companies such as BioMerieux, Boehringer Mannheim (now Roche) and GSK. Currently Director and Country Manager at MP Biomedicals, she is responsible for all sales, management, and regulatory functions. Karen has a Bachelor of Applied Science and Graduate Diploma in Marketing from UTS, Sydney and has been a member of the IVD Australia Technical and Regulatory Standing Committee since 2011.

Antionette Violo

Regional Sales Director, Applied Genomics and Discovery, PerkinElmer
Director and General Manager, PerkinElmer Oceania

Antoniette's 30-year career in the Life Sciences and IVD industry began as a researcher in the Academic sector. She entered the commercial role, working for Linbrook International, where she held several roles both in commercial and product management. She was approached to establish the Life Sciences and Diagnostic Business for PerkinElmer over 20 years ago. Within PerkinElmer she has held commercial roles within Australia and in Asia Pacific. She has a Bachelor of Science degree with Hons, specializing in the field of Genetics and Immunology.

Tony Feneziani

Head of Research Solutions ANZ, Merck Group

Tony has over 25 years commercial experience in the in vitro diagnostic and life sciences industries. During this time, Tony has undertaken a range of leadership roles including commercial operations, sales and marketing and business development. Tony's current role at Merck also includes Country Leadership Team membership of the Merck Life Sciences operation in ANZ.

Jenny Carson

Head of Marketing, Laboratory Diagnostics, Siemens Healthineers ANZ

Jenny commenced her career as medical scientist in 1985 and advanced to Senior Scientific Officer before leaving the laboratory to join the IVD industry in 1998. Throughout her 23-year IVD career she has held various roles including Applications Specialist, Product Manager, Regional Sales Manager, Business Unit Manager and is currently Head of Marketing. Jenny holds a Bachelor of Applied Science (MLS) from Charles Sturt University and a Graduate Diploma of Management from Macquarie Graduate School of Management.

Nicolas Latouche

Bio-Rad

Nic has more than 18-years in the healthcare industry, working for companies that offer solutions to both the diagnostics and life science research market. Starting at Becton Dickinson as an application specialist after completing a PhD at Sydney University, Nic went on to sales, sales and marketing management, supporting customers in the life science segment. During this time, he also completed an MBA at Deakin University Business School, focusing on general management and law for business (including corporation law).

Sebastian D'Angelo

General Manager, Laboratory Diagnostics Division, Siemens Healthcare – Australia & New Zealand.

Sebastian has over 30 years' experience within the Australian IVD industry, having worked as a medical scientist in public pathology laboratories before moving to senior roles at Chiron Diagnostics and Bayer Diagnostics and now at Siemens Healthcare Diagnostics. Sebastian holds a Bachelor of Applied Science (MLS) degree from RMIT University and a Master of Marketing degree from the Melbourne Business School. He is a Member of the Australian Institute of Company Directors.

John Crothers

Chair, Pathology Awareness Australia
Regional Director, Abbott Diagnostics Pty Ltd

John Crothers is the Regional Director for Australia and New Zealand. Prior to the role in Australia, John was the Commercial Director for Asia Pacific and has also had several years in US Marketing. With over 25 years' experience in the pathology industry in both the laboratory and IVD, the appreciation of the value of the industry in healthcare is a passion that John continues to pursue. John has a BSc (MLS) from RMIT and a Graduate Diploma in Business Administration from Swinburne University.

Rayden Rivett

General Manager, Cepheid Holdings Pty Ltd

Rayden has been continuously involved in the IVD Industry since 1979 working in sales, marketing and senior management. For 15 years he was Managing Director of bioMérieux in Australia and since 2006 has worked in the USA, Asia-Pacific and more recently in establishing Australian subsidiaries for overseas-based IVD companies. Rayden has represented the IVD sector in the past, being a Board member of MIAA (now MTAA) from 1999 to 2006 and its Vice-Chair (2003-2004), a member of their Diagnostic/IVD Standing Committee 1994-2001, member of the Market Development Committee (1997-2003) and its Chair (2000-2002).

EVENTS SUBSEQUENT TO REPORTING DATE

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Company, the results of those operations or the state of affairs of the Company in future financial years.

LIKELY DEVELOPMENTS

The Company will continue to pursue its principal activities at a surplus. It is not expected that the results in future years will be adversely affected by the continuation of those operations.

Future disclosure of information regarding likely developments in the operations of the Company in future financial years and the expected results of those operations is likely to result in unreasonable prejudice to the Company. Accordingly, this information has not been disclosed in this report.

ENVIRONMENTAL REGULATIONS

The Company's operations are not regulated by any significant environmental regulation under Australian Law.

INDEMNIFICATION AND INSURANCE OF OFFICERS AND AUDITORS

Insurance premiums

During the financial year, the company has paid or agreed to pay premiums in respect of such insurance contracts for the year ended 30 June 2020. Such insurance contracts insure against certain liability (subject to specific exclusions) persons who are or have been directors or executive officers of the Company.

The Directors have not included details of the nature of the liabilities covered or the amount of the premium paid in respect of the directors' and officers' liability insurance contracts, as such disclosure is prohibited under the terms of the contracts.

Indemnification

Since the end of the previous financial year, the Company has not indemnified or made a relevant agreement for indemnifying against a liability any person who is or has been an officer or auditor of the Company.

MEMBERS GUARANTEE

Each member of the Company undertakes to contribute to the assets of the Company in the event of it being wound up, while he/she is a member, or within one year after he/she ceases to be a member, for the payment of debts and liabilities of the Company, charges and expenses of a winding up, and for the adjustment of the rights of the contributions among themselves, such amounts as may be required not exceeding twenty five dollar ($25.00).

MEETINGS OF DIRECTORS

The number of meetings of the company's Board of Directors ('the Board') held during the year ended 30 June 2021, and the number of meetings attended by each director were:

	FULL BOARD	
	ATTENDED	HELD
Mr David Basseal	11	11
Mr Vito Trifilo (Treasurer)	11	11
Mr Mark Volling	7	8
Ms Sally Hickman	9	11
Ms Antoniette Violo	9	11
Ms Karen MacLeod	11	11
Mr Tony Feneziani	7	8
Ms Jenny Carson	8	8
Mr Nicolas Latouche	4	4
Mr Sebastian D'Angelo	4	4
Mr John Crothers	4	4
Mr Rayden Rivett	4	4

Held: represents the number of meetings held during the time the director held office.

AUDITOR'S INDEPENDENCE DECLARATION

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the directors

Mr David Basseal
Chair

Mr Vito Trifilo
Treasurer

24th of September 20211

To the Board of Directors of Pathology Technology Australia

Auditor's Independence Declaration under section 307C of the Corporations Act 2001

As lead audit director for the audit of the financial statements of Pathology Technology Australia Limited for the financial year ended 30 June 2021, I declare that to the best of my knowledge and belief, there have been no contraventions of:

(a) the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and

(b) any applicable code of professional conduct in relation to the audit.

Yours sincerely

Nexia Sydney Audit Pty Ltd

Mark Boyle
Director, Sydney

Dated: 24 September 2021

Sydney Office
Level 16, 1 Market Street , Sydney NSW 2000
PO Box H195 Australia Square NSW 1215
p +61 2 9251 4600 **f** +61 2 9251 7138
e info@nexiacourt.com.au **w** www.nexia.com.au

Financial **Statements**

General **Information**

The financial statements cover Pathology Technology Australia Limited as an individual entity. The financial statements are presented in Australian dollars, which is Pathology Technology Australia Limited's functional and presentation currency.

Pathology Technology Australia Limited is a not-for-profit unlisted public company limited by guarantee.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 23 September 2021. The directors have the power to amend and reissue the financial statements.

Statement of Profit or Loss and **other comprehensive income**

For the year ended 30 June 2021

	Note	2021	2020
Revenue	3	**616,650**	485,584
Government grants	4	**26,343**	43,905
Interest revenue		**2,288**	4,887
Expenses			
Employee benefits expense	5	**(290,837)**	(278,837)
Depreciation and amortisation expense		**(3,154)**	(1,386)
Administrative expenses		**(237,727)**	(153,117)
Surplus/(deficit) before income tax expense		**113,563**	101,036
Income tax expense		**-**	-
Surplus after income tax expense for the year	14	**113,563**	101,036
Other comprehensive income for the year, net of tax		**-**	-
Total comprehensive income for the year		**113,563**	101,036

Statement of **Financial Position**

As at 30 June 2021

	Note	2021	2020
ASSETS			
Current Assets			
Cash and cash equivalents	6	**543,216**	310,316
Trade and other receivables	7	**3,960**	15,690
Other	8	**52,183**	3,287
Total current assets		**599,359**	329,293
Non-current assets			
Plant and equipment	9	**2,661**	5,815
Total non-current assets		**2,661**	5,815
Total assets		**602,020**	335,108
LIABILITIES			
Current liabilities			
Trade and other payables	10	**27,792**	17,336
Employee benefits	11	**29,387**	24,281
Contract liabilities	12	**149,235**	13,728
Total current liabilities		**206,414**	55,345
Non-current liabilities			
Employee benefits	13	**7,272**	4,992
Total non-current liabilities		**7,272**	4,992
Total liabilities		**213,686**	60,337
Net Assets		**388,334**	274,771
EQUITY			
Retained surpluses	14	**388,334**	274,771
Total Equity		**388,334**	274,771

Statement of **changes in equity**

For the year ended 30 June 2021

	RETAINED SURPLUS	TOTAL EQUITY
Balance at 1 July 2019	**173,735**	173,735
Surplus after income tax expense for the year	**101,036**	101,036
Other comprehensive income for the year, net of tax	**-**	-
Balance at 30 June 2020	**274,771**	274,771
Balance at 1 July 2020	**274,771**	274,771
Surplus after income tax expense for the year	**113,563**	113,563
Other comprehensive income for the year, net of tax	**-**	-
Total comprehensive income for the year	**113,563**	113,563
Balance at 30 June 2021	**388,334**	388,334

Statement of **cash flows**

For the year ended 30 June 2021

	Note	2021	2020
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers (inclusive of GST)		**852,154**	377,912
Payments to suppliers (inclusive of GST)		**(648,052)**	(486,067)
		204,102	(108,155)
Interest received		**2,455**	5,945
Government grants		**26,343**	43,905
Net cash from/(used in) operating activities		**232,900**	(58,305)
CASH FLOWS FROM INVESTING ACTIVITIES			
Payments for property, plant and equipment	9	**-**	(5,452)
Net cash used in investing activities		**-**	(5,452)
CASH FLOWS FROM FINANCING ACTIVITIES			
Net cash from financing activities		**-**	-
Net increase/(decrease) in cash and cash equivalents		**232,900**	(63,757)
Cash and cash equivalents at the beginning of the financial year		**310,316**	374,073
Cash and cash equivalents at the end of the financial year	6	**543,216**	310,316

Notes to the **Financial Statement**

30 June 2021

NOTE 1. SIGNIFICANT ACCOUNTING POLICIES

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

(i) New or amended Accounting Standards and Interpretations adopted

The company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

(ii) Basis of preparation

These general-purpose financial statements have been prepared in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and Interpretations issued by the Australian Accounting Standards Board ('AASB'), and the Corporations Act 2001, as appropriate for not-for profit-oriented entities.

Historical cost convention

The financial statements have been prepared under the historical cost convention.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2.

(iii) Revenue recognition

The company recognises revenue as follows:

Revenue from contracts with customers

Revenue is recognised at an amount that reflects the consideration to which the company is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the company: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts, rebates and refunds, and any other contingent events. Such estimates are determined using either the 'expected value' or 'most likely amount' method. The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognised as a refund liability.

Membership

Membership revenue is recognised over the period of the membership.

Grants

Grant revenue is recognised in profit or loss when the company satisfies the performance obligations stated within the funding agreements.

If conditions are attached to the grant which must be satisfied before the company is eligible to retain the contribution, the grant will be recognised in the statement of financial position as a liability until those conditions are satisfied.

Interest

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

Other revenue

Other revenue is recognised when it is received or when the right to receive payment is established.

Volunteer services

The company has elected not to recognise volunteer services as either revenue or other form ofcontributionreceived.Assuch,anyrelatedconsumptionorcapitalisationofsuchresourcesreceivedisalsonot recognised.

(iv) Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the company's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the company's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

(v) Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

(vi) Trade and other receivables

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

(vii) Plant and equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is calculated on a straight-line basis to write off the net cost of each item of plant and equipment over their expected useful lives as follows:

Furniture, fixtures & fittings	3-5 years
Computer equipment	3 years

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

An item of plant and equipment is derecognised upon disposal or when there is no future economic benefit to the company. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss.

(viii) Impairment of non-financial assets

Non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit.

(ix) Trade and other payables

These amounts represent liabilities for goods and services provided to the company prior to the end of the financial year and which are unpaid. Due to their short-term nature, they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

(x) Employee benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled.

Other long-term employee benefits

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are measured at the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on national government bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

(xi) Contract liabilities

Contract liabilities represent the company's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration, or when the company recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the company has transferred the goods or services to the customer.

(xii) Fair value measurement

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

(xiii) Goods and Services Tax ('GST') and other similar taxes

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

NOTE 2. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND ASSUMPTIONS

(i) Estimation of useful lives of assets

The company determines the estimated useful lives and related depreciation and amortisation charges for its plant and equipment. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

(ii) Employee benefits provision

As discussed in note 1, the liability for employee benefits expected to be settled more than 12 months from the reporting date are recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

(iii) Coronavirus (COVID-19) pandemic

Judgement has been exercised in considering the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the company based on known information. This consideration extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the company operates. Other than as addressed in specific notes, there does not currently appear to be either any significant impact upon the financial statements or any significant uncertainties with respect to events or conditions which may impact the company unfavourably as at the reporting date or subsequently as a result of the Coronavirus (COVID-19) pandemic.

NOTE 3. REVENUE

	2021	2020
REVENUE FROM CONTRACTS WITH CUSTOMERS		
Membership revenue	**604,650**	485,584
OTHER REVENUE		
Other Revenue	**12,000**	-
Revenue	**616,650**	485,584

Disaggregation of revenue

The disaggregation of revenue from contracts with customers is as follows:

	2021	2020
TIMING OF REVENUE RECOGNITION		
Goods transferred at a point in time	**12,000**	-
Services transferred over time	**604,650**	485,584
	616,650	485,584

NOTE 4. GOVERNMENT GRANTS

	2021	2020
Government stimulus package	**26,343**	43,905

NOTE 5. EMPLOYEE BENEFITS EXPENSE

	2021	2020
Wages and salaries	**258,965**	240,064
Superannuation	**24,488**	22,692
Provision movements	**7,384**	16,081
	290,837	278,837

NOTE 6. CURRENT ASSETS - CASH AND CASH EQUIVALENTS

	2021	2020
Cash at bank	**223,056**	70,316
Cash on deposit	**320,160**	240,000
	543,216	310,316

NOTE 7. CURRENT ASSETS - TRADE AND OTHER RECEIVABLES

	2021	2020
Trade and other receivables	**3,960**	1,055
Other receivables	**-**	14,635
	3,960	15,690

NOTE 8. CURRENT ASSETS - OTHER

	2021	2020
Prepayments	**52,183**	3,287

NOTE 9. NON-CURRENT ASSETS - PLANT AND EQUIPMENT

	2021	2020
Computer equipment - at cost	**8,501**	8,501
Less: Accumulated depreciation	**(5,840)**	(2,686)
	2,661	5,815

Reconciliations

Reconciliations of the written down values at the beginning and end of the current financial year are set out below:

	COMPUTER EQUIPMENT	TOTAL
Balance at 1 July 2020	**5,815**	5,815
Depreciation expense	**(3,154)**	(3,154)
Balance at 30 June 2021	**2,661**	2,661

NOTE 10. CURRENT LIABILITIES - TRADE AND OTHER PAYABLES

	2021	2020
Other payables	**6,220**	5,692
GST collected	**3,551**	1,491
Accrued expenses	**18,021**	10,153
	27,792	17,336

NOTE 11. CURRENT LIABILITIES - EMPLOYEE BENEFITS

	2021	2020
Annual leave	**29,387**	24,281

NOTE 12. CURRENT LIABILITIES - CONTRACT LIABILITIES

	2021	2020
Revenue received in advance	**149,235**	13,728

NOTE 13. NON-CURRENT LIABILITIES - EMPLOYEE BENEFITS

	2021	2020
Long service leave	**7,272**	4,992

NOTE 14. EQUITY - RETAINED SURPLUSES

	2021	2020
Retained surpluses at the beginning of the financial year	**274,771**	173,735
Surplus after income tax expense for the year	**113,563**	101,036
Retained surpluses at the end of the financial year	**388,334**	274,771

NOTE 15. SUPERANNUATION COMMITMENTS

The company has a legal obligation to contribute superannuation for all employees. The company contributes to complying accumulation superannuation plans.

NOTE 16. CONTINGENT LIABILITIES

There are no contingent liabilities that have been incurred by the Company in relation to 2021 or 2020.

NOTE 17. RELATED PARTY TRANSACTIONS

Transactions with related parties

Key management personnel include the Directors and the Chief Executive Officer. All Directors are honorary and as such no payments are made to the Directors. Short term benefits received by key management personnel during the year were $235,938 (2020: $219,069). No other benefits were received or provided.

Transactions with related parties

Unless otherwise stated, none of the transactions incorporate special terms and conditions and no guarantees were given or received.

The only transactions with related parties of Pathology Technology Australia Limited were membership subscription fees received from organisations in which the Directors are employed.

Loans to/from related parties

There were no loans to or from related parties at the current and previous reporting date.

NOTE 18. EVENTS AFTER THE REPORTING PERIOD

No matter or circumstance has arisen since 30 June 2021 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.

Director's **Declaration**

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Australian Accounting Standards - Reduced Disclosure Requirements, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the company's financial position as at 30 June 2021 and of its performance for the financial year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors

Mr David Basseal
Chair

Mr Vito Trifilo
Treasurer

24th of September 20211

Nexia Australia

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF PATHOLOGY TECHNOLOGY AUSTRALIA LIMITED

REPORT ON THE AUDIT OF THE FINANCIAL REPORT

Opinion

We have audited the financial report of Pathology Technology Australia Limited (the Company), which comprises the statement of financial position as at 30 June 2021, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration.

In our opinion, the accompanying financial report of the Company is in accordance with the Corporations Act 2001, including:

i) giving a true and fair view of the Company's financial position as at 30 June 2021 and of its financial performance for the year then ended; and

ii) complying with Australian Accounting Standards - Reduced Disclosure Requirements and the Corporations Regulations 2001.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the 'auditor's responsibilities for the audit of the financial report' section of our report. We are independent of the Company in accordance with the Corporations Act 2001 and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The directors are responsible for the other information. The other information comprises the information in Pathology Technology Australia Limited's annual report for the year ended 30 June 2021, but does not include the financial report and the auditor's report thereon. Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of the other information we are required to report that fact. We have nothing to report in this regard.

Directors' responsibility for the financial report

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibility for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at The Australian Auditing and Assurance Standards Board website at: www.auasb.gov.au/auditors_files/ar4.pdf. This description forms part of our auditor's report.

Nexia Sydney Audit Pty Ltd

Mark Boyle
Director
Sydney

Dated: 24 September 2021

Pathology Technology **Australia Members**

Abacus dx Pty Ltd
AB Sciex
Abbott Australasia Pty Ltd
Agilent Technologies Australia Pty Ltd
Anteotech Ltd
Astral Scientific Pty Ltd
Atomo Diagnostics
Australasian Medical and Scientific Ltd
Becton Dickinson Pty Ltd
Beckman Coulter
BGI
Binding Site Pty Ltd
Biocelect Pty Limited
bioMérieux Australia Pty Ltd
Bio-Rad Laboratories Pty Ltd
Cellmid Limited
Cepheid Holdings Pty Ltd
Diagnostica Stago Pty Ltd
DiaSorin Australia Pty Ltd
Eppendorf South Pacific Pty Ltd
ESL Biosciences Australia (2012) Pty Ltd
Genetic Signatures Limited
Grifols Australia Pty Ltd
Hologic (Australia) Pty Ltd
Hough Pharma Pty Ltd
Illumina Australia Pty Ltd
Integrated Sciences Pty Ltd
Leica Biosystems
Life Bioscience Pty Ltd
Lumos Diagnostics Holdings Pty Ltd
Merck Millipore Australia Pty Ltd
Minomic International
MP Biomedicals Australasia Pty Ltd
Myriad Genetics
NeedleCalm
Paragon Therapeutic Technologies Pty Ltd
PerkinElmer Pty Ltd
Pro-Health Asia Pacific Pty Ltd
QIAGEN Pty Ltd
Radiometer
Rhinomed
Roche Diagnostics Australia Pty Ltd
Siemens Healthcare Pty Ltd
SJ Alder Pty Ltd
Speciality Diagnostix Pty Limited
SpeeDx Pty Ltd
SureScreen Australia Ltd
Sysmex Australia Pty Ltd
Tecan Australia Pty Ltd
ThermoFisher Scientific Australia Pty Ltd
Trajan Scientific Australia Pty Ltd
Werfen Australia Pty Ltd



PATHOLOGY
TECHNOLOGY
AUSTRALIA

PO Box 298
Parramatta CBD BC
NSW 2124 Australia
Email: info@pathologytechnology.org.au

Dean Whiting
Mobile: +61 (0)497 777 688
Email: ceo@pathologytechnology.org.au

Pathology Technology Australia | Annual report 2020 | **pathologytechnology.org.au**

ABN 31 137 771 63